Impedimed (ASX:IPD) Interest Paid: A$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Impedimed Interest Paid?

Impedimed ASX:IPD Interest Paid is A$0.00 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Impedimed's Interest Paid for the six months ended in Dec. 2025 was A$0.00 Mil.

Impedimed's Interest Paid for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Impedimed Interest Paid Related Terms

Impedimed Interest Paid Historical Data

* Premium members only.

The historical data trend for Impedimed's Interest Paid can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Impedimed Interest Paid Chart

Impedimed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Interest Paid
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Impedimed Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Paid Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Impedimed Interest Paid Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Interest Paid represents interest paid on loans, debt or borrowings, in the direct cash flow method.

Interest Paid for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Paid →
What does a Interest Paid of A$0.00 Mil mean?
Impedimed (ASX:IPD) has a Interest Paid of A$0.00 Mil as of Dec. 2025. Interest Paid represents interest paid on loans, debt or borrowings in direct cash flow method. View historical data for Impedimed and its competitors.
Is Impedimed's Interest Paid too high?
Impedimed's current Interest Paid is A$0.00 Mil.
How does Impedimed's Interest Paid compare to ABT and SYK?
Impedimed's Interest Paid of A$0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Paid for a Medical Devices & Instruments company?
A good Interest Paid depends on the Medical Devices & Instruments industry context. However, Interest Paid should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Paid mean?
A high Interest Paid can signal that a stock is expensive relative to its fundamentals. Interest Paid represents interest paid on loans, debt or borrowings in direct cash flow method. View historical data for Impedimed and its competitors. Impedimed's current Interest Paid is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impedimed stock overvalued right now?
Impedimed (ASX:IPD) has a current Interest Paid of A$0.00 Mil. The current Interest Paid is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Paid calculated?
Interest Paid is calculated from a company's financial statements. For Impedimed (ASX:IPD), the current Interest Paid is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Impedimed Business Description

Other Exchanges IPDQF:USA
Address 5900 Pasteur Court, Suite 125, Carlsbad, CA, USA, 92008
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.